What is bioprocessing and why is Cytiva important?

Bioprocessing refers to the manufacturing processes used to produce biopharmaceutical drugs — including monoclonal antibodies, cell therapies, gene therapies, and vaccines. Cytiva (formerly GE Healthcare Life Sciences, acquired by Danaher in 2020) supplies the chromatography systems, filtration equipment, bioreactors, and consumables (resins, filters) used throughout the biopharmaceutical manufacturing process. These are mission-critical supplies where any disruption to production affects drug manufacturing, creating high switching costs and recurring consumable revenue.

What was the biopharma inventory destocking cycle and how did it affect Danaher?

During COVID, biopharma companies dramatically increased purchases of bioprocessing equipment and consumables (for vaccine production and drug manufacturing scale-up). Post-COVID, these companies had excess inventory that needed to be consumed before they would purchase new supplies. This 'destocking' cycle lasted approximately 2022-2024 and significantly reduced Danaher's Cytiva bioprocessing revenues. The cycle was expected to normalize as biopharma companies drew down their excess inventory and returned to normal purchasing patterns.

What is an intraoral scanner and why is it important in dentistry?

An intraoral scanner (like Envista's iTero) is a handheld device that digitally scans a patient's teeth and gums to create a precise 3D digital model of the patient's dentition — replacing traditional physical impressions (the molding process using dental putty). Digital scans are faster, more comfortable for patients, more accurate, and can be transmitted electronically to orthodontic labs for clear aligner fabrication or to implant laboratories. The digital workflow enabled by intraoral scanners is reshaping dental practice efficiency and treatment planning.

Data as of: June 16, 2026

brimindinvest.com / compare / nvst-vs-danaher-dxLIVE

NVST

Envista Holdings Corporation · Healthcare - Dental Products

N/A

N/A this month

VERSUS

COMPARE

DHR

Danaher Corporation · Healthcare - Life Science Tools & Diagnostics

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

NVST N/A

DHR N/A

1Y Returni

NVST N/A

DHR N/A

Fwd P/Ei

NVST N/A

DHR N/A

Target Up.i

NVST N/A

DHR N/A

Op. Margini

NVST N/A

DHR N/A

Quick take

NVST vs DHR Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

NVST (Envista Holdings) was spun off from DHR (Danaher) in 2019 with the dental products portfolio, while Danaher retained life science tools, diagnostics, and environmental — both companies use continuous improvement methodologies but at very different scales and in different healthcare subsectors. Danaher is a larger, more diversified platform; Envista is a focused dental products pure-play.

NVST vs DHR is focused dental products spinoff (Envista's implants and orthodontics) versus diversified healthcare and life science tools compounder (Danaher's bioprocessing, diagnostics, and DBS-powered acquisition platform) — parent versus child in life science tools and healthcare.

Want a full valuation workup? 46-section report — AI Score, Monte Carlo forecast, bull/bear case, DCF, and more.

DHR Report

Normalized 1Y performance

NVST

DHR

Not enough data to chart yet.

Recent returns

NVST

DHR

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

NVST

Price target data unavailable

N/A

DHR

Price target data unavailable

N/A

Who should consider this stock?

NVST may suit investors who:

Want focused dental products exposure through Nobel Biocare implants, Ormco orthodontics, and iTero intraoral scanners in the growing global dental market
Value Envista's path to independent profitability improvement as the company scales and optimizes operations following the Danaher spin-off
See dental implant and clear aligner market growth as structural tailwinds as aging populations and increasing dental aesthetics consciousness drive treatment volumes

DHR may suit investors who:

Want the Danaher Business System compounder with bioprocessing, diagnostics, and life science tools as the core platform — one of the most respected capital allocation track records in healthcare
Value Cytiva's bioprocessing recovery as a catalyst for Danaher's growth re-acceleration following the 2022-2024 biopharma inventory destocking cycle
Prefer diversified healthcare and life science exposure versus focused dental-only or pure diagnostic pure-plays

Performance & AI score

Performance & AI score
Metric	NVST	DHR
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	NVST	DHR
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Full DCF model for DHR

Growth, profitability & risk

Growth, profitability & risk
Metric	NVST	DHR
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	N/A	N/A
Dividend growth streaki	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

NVST max drawdowniN/A

DHR max drawdowniN/A

NVST max wkly dropiN/A

DHR max wkly dropiN/A

5Y risk snapshot

NVST max drawdowniN/A

DHR max drawdowniN/A

NVST max wkly dropiN/A

DHR max wkly dropiN/A

10Y risk snapshot

NVST max drawdowniN/A

DHR max drawdowniN/A

NVST max wkly dropiN/A

DHR max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	NVST	DHR
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

NVST

+2.8%BUY

DHR

+1.1%HOLD

Next 30 trading days

NVST

+6.4%BUY

DHR

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	NVST	DHR
Company	Envista Holdings Corporation	Danaher Corporation
Sector	Healthcare - Dental Products	Healthcare - Life Science Tools & Diagnostics
Industry	N/A	N/A
Core business	Envista Holdings is a dental products company spun off from Danaher in 2019, offering dental implants, orthodontics (Ormco, iTero), and dental consumables through its Specialty Products & Technologies and Equipment & Consumables segments — serving dental practitioners globally.	Danaher is a global science and technology company providing instruments, reagents, and software for life science research (Cytiva for bioprocessing, Leica for microscopy), diagnostics (Radiometer, HemoCue), and environmental and applied solutions — operating through an acquisition and continuous improvement methodology known as the Danaher Business System (DBS).
Investor focus	Investors track Envista's implant market share, iTero intraoral scanner adoption, clear aligner treatment attachment rate, organic revenue growth, and the company's ability to improve operating margins as an independent company after the Danaher spin-off.	Investors track Danaher's bioprocessing revenue (Cytiva — a key biotech/biopharma tool supplier), core revenue growth, operating margin expansion through DBS, and capital allocation between organic investment and M&A.

NVST strengths

Strong dental implant brands (Nobel Biocare, Implant Direct) and orthodontic technology (Ormco, iTero intraoral scanner) give Envista positions in premium segments of the dental market
Clear aligner market integration — iTero scanners are used in Invisalign workflows, creating a relationship with Align Technology and a foothold in the growing clear aligner orthodontic market
Dental procedures are generally non-discretionary maintenance expenditures rather than purely elective, providing demand resilience through economic cycles

DHR strengths

Danaher Business System (DBS) — the proprietary continuous improvement methodology based on Toyota Production System principles — consistently improves acquired company operating performance, creating compounding value from acquisitions
Bioprocessing franchise (Cytiva) provides mission-critical equipment and consumables for biopharmaceutical drug manufacturing — an essential position in the biopharma supply chain
Diversified platform across life sciences, diagnostics, and water quality provides multiple exposure to large and growing markets with different cyclical characteristics

Risks to watch — NVST

Envista operates independently after the Danaher spin-off and must demonstrate it can grow and improve margins without Danaher's operational system (DBS) and balance sheet support
Dental implant market competition from Straumann, Envista's Nobel Biocare, and others intensifies as market leaders compete on pricing, technology, and distribution
Consumer spending on elective dental procedures (cosmetic work, implants) can be deferred during economic downturns, making revenue timing sensitive to consumer confidence

Risks to watch — DHR

Bioprocessing inventory destocking cycle (2022-2024) significantly reduced Cytiva revenue as biopharma companies drew down COVID-era inventory excesses — recovery timing is critical for Danaher's growth re-acceleration
Large acquisitions require successful DBS integration to achieve value — poor acquisition choices or integration execution can be value-destructive despite the strong DBS system
Life science research spending is tied to NIH and private biopharma R&D budgets, which can fluctuate with government budget changes and biopharma industry spending cycles

Frequently asked questions

The Danaher Business System is a continuous improvement methodology based on lean manufacturing principles (Toyota Production System) that Danaher applies to all its acquisitions. DBS includes kaizen events (rapid improvement workshops), visual management, and standardized problem-solving frameworks that systematically reduce waste, improve quality, and increase productivity. DBS is why Danaher acquires companies and then consistently improves their operating metrics — it is the core intellectual capital behind Danaher's long track record of value creation.

Interactive comparison engine

Compare more than two at a time

This page is a fixed writeup on NVST and DHR. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.

Up to 5 tickers at once

Add three more names beside NVST and DHR, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.

Scoreboard verdict

AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.

Full risk suite

Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.

Correlation heatmap

Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.

Valuation vs profitability

A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.

Holdings overlap and CSV export

For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.

Open NVST vs DHR in the engine See what's included

Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

In-Depth Reports

Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.

DHR Report

Related comparisons